Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.

Tingting Zhang | Weiwei Tian | Shuang Wei | Xinyi Lu | Jing An | Shaolong He | Jie Zhao | Zhilin Gao | Li Li | Ke Lian | Qiang Zhou | Huilai Zhang | Liang Wang | Liping Su | Huicong Kang | Ting Niu | Ailin Zhao | Jing Pan | Qingqing Cai | Zhenshu Xu | Wenming Chen | Hongmei Jing | Peng Li | Wanhong Zhao | Yang Cao | Jianqing Mi | Tao Chen | Yuan Chen | Ping Zou | Veronika Lukacs-Kornek | Christian Kurts | Jian Li | Xiansheng Liu | Qi Mei | Yicheng Zhang | Jia Wei
Experimental hematology & oncology | 2023

The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

Pubmed ID: 37501090

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: 2023 COVID-19 Emergency Project of Shanxi Bethune Hospital,
    Id: 2023xg05-2
  • Agency: 2023 COVID-19 Emergency Project of Shanxi Bethune Hospital,
    Id: 2023xg02
  • Agency: 2023 COVID-19 Emergency Project of Shanxi Health Commission,
    Id: 2023XG005
  • Agency: 2023 COVID-19 Emergency Project of Shanxi Health Commission,
    Id: 2023XG001
  • Agency: National Natural Science Foundation of China,
    Id: 82270175
  • Agency: National Natural Science Foundation of China,
    Id: 82070217
  • Agency: Natural Science Foundation of Fujian Province of China,
    Id: 2021J02040
  • Agency: Sino-German Center for Research Promotion (SGC)'s rapid Response Funding for Bilateral Collaborative Proposals Between China and Germany in COVID-19 Related Research,
    Id: C-0065
  • Agency: Sino-German Center for Research Promotion (SGC)'s rapid Response Funding for Bilateral Collaborative Proposals Between China and Germany in COVID-19 Related Research,
    Id: C-0065
  • Agency: National High Technology Research and Development Program of China,
    Id: 2021YFA1101504

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


PubMed (tool)

RRID:SCR_004846

Public bibliographic database that provides access to citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites. PubMed citations and abstracts include fields of biomedicine and health, covering portions of life sciences, behavioral sciences, chemical sciences, and bioengineering. Provides access to additional relevant web sites and links to other NCBI molecular biology resources. Publishers of journals can submit their citations to NCBI and then provide access to full-text of articles at journal web sites using LinkOut.

View all literature mentions